Free Trial

Bank of New York Mellon Corp Acquires 10,255 Shares of The Clorox Company (NYSE:CLX)

Clorox logo with Consumer Staples background

Bank of New York Mellon Corp increased its holdings in shares of The Clorox Company (NYSE:CLX - Free Report) by 1.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 826,158 shares of the company's stock after purchasing an additional 10,255 shares during the period. Bank of New York Mellon Corp owned approximately 0.67% of Clorox worth $121,652,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Sonora Investment Management Group LLC grew its stake in Clorox by 2.5% during the first quarter. Sonora Investment Management Group LLC now owns 2,940 shares of the company's stock worth $433,000 after purchasing an additional 72 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in Clorox by 0.6% during the first quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 13,266 shares of the company's stock worth $1,953,000 after purchasing an additional 73 shares during the period. Sound View Wealth Advisors Group LLC grew its stake in Clorox by 6.1% during the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,345 shares of the company's stock worth $218,000 after purchasing an additional 77 shares during the period. Wedbush Securities Inc. grew its stake in Clorox by 1.2% during the fourth quarter. Wedbush Securities Inc. now owns 7,624 shares of the company's stock worth $1,238,000 after purchasing an additional 94 shares during the period. Finally, Independent Advisor Alliance grew its stake in Clorox by 0.7% during the fourth quarter. Independent Advisor Alliance now owns 15,008 shares of the company's stock worth $2,438,000 after purchasing an additional 104 shares during the period. Institutional investors and hedge funds own 78.53% of the company's stock.

Wall Street Analysts Forecast Growth

CLX has been the subject of several recent analyst reports. JPMorgan Chase & Co. decreased their target price on Clorox from $151.00 to $144.00 and set a "neutral" rating for the company in a research note on Tuesday, May 6th. UBS Group reduced their price objective on Clorox from $176.00 to $154.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. Wells Fargo & Company reduced their price objective on Clorox from $142.00 to $135.00 and set an "equal weight" rating for the company in a research note on Wednesday. Evercore ISI set a $140.00 price objective on Clorox and gave the company an "underperform" rating in a research note on Tuesday, May 6th. Finally, Citigroup reduced their price objective on Clorox from $165.00 to $150.00 and set a "neutral" rating for the company in a research note on Monday, April 14th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, Clorox currently has a consensus rating of "Hold" and a consensus price target of $148.92.

Get Our Latest Stock Analysis on CLX

Insider Activity

In other Clorox news, Director Pierre R. Breber purchased 4,000 shares of the company's stock in a transaction that occurred on Wednesday, May 7th. The shares were acquired at an average cost of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the acquisition, the director owned 4,000 shares of the company's stock, valued at $546,280. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.57% of the stock is currently owned by insiders.

Clorox Stock Up 1.8%

Shares of NYSE:CLX traded up $2.26 during mid-day trading on Thursday, hitting $128.26. 466,128 shares of the company traded hands, compared to its average volume of 1,404,740. The stock has a market cap of $15.81 billion, a P/E ratio of 23.03, a P/E/G ratio of 3.07 and a beta of 0.51. The company has a current ratio of 0.74, a quick ratio of 0.44 and a debt-to-equity ratio of 13.07. The Clorox Company has a 12-month low of $117.35 and a 12-month high of $171.37. The stock has a 50-day moving average price of $128.74 and a two-hundred day moving average price of $143.08.

Clorox (NYSE:CLX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.12). The company had revenue of $1.67 billion for the quarter, compared to analysts' expectations of $1.74 billion. Clorox had a net margin of 9.89% and a return on equity of 324.23%. The firm's quarterly revenue was down 8.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.71 EPS. On average, equities research analysts forecast that The Clorox Company will post 7.15 earnings per share for the current year.

About Clorox

(Free Report)

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

Further Reading

Institutional Ownership by Quarter for Clorox (NYSE:CLX)

Should You Invest $1,000 in Clorox Right Now?

Before you consider Clorox, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clorox wasn't on the list.

While Clorox currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines